Hypertrophic cardiomyopathy resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Steven Bellm (talk | contribs) (Created page with "<div style="width: 90%;"> __NOTOC__ {{CMG}}; {{AE}} {| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; to...") |
Steven Bellm (talk | contribs) No edit summary |
||
| Line 25: | Line 25: | ||
==Overview== | ==Overview== | ||
[[Hypertrophic Cardiomyopathy]] is defined by LV hypertrophy associated with nondilated ventricular chambers | [[Hypertrophic Cardiomyopathy]] is defined by LV hypertrophy associated with nondilated ventricular chambers. HCM is usually recognized by maximal LV wall thickness ≥15 mm. Wall thickness of 13 to 14 mm is considered borderline if there are other compelling information (eg, family history of HCM), based on echocardiography. The diagnostic imaging mainly focused on echocardiography, however cardiovascular magnetic resonance (CMR) is used with increasing frequency.<ref name="pmid22093723">{{cite journal| author=American College of Cardiology Foundation/American Heart Association Task Force on Practice. American Association for Thoracic Surgery. American Society of Echocardiography. American Society of Nuclear Cardiology. Heart Failure Society of America. Heart Rhythm Society et al.| title=2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=J Thorac Cardiovasc Surg | year= 2011 | volume= 142 | issue= 6 | pages= e153-203 | pmid=22093723 | doi=10.1016/j.jtcvs.2011.10.020 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22093723 }} </ref> | ||
==Classification== | ==Classification== | ||
Revision as of 15:33, 6 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
| Hypertrophic cardiomyopathy resident survival guide Microchapters |
|---|
| Overview |
| Classification |
| Causes |
| FIRE |
| Diagnosis |
| Treatment |
| Do's |
| Dont's |
Overview
Hypertrophic Cardiomyopathy is defined by LV hypertrophy associated with nondilated ventricular chambers. HCM is usually recognized by maximal LV wall thickness ≥15 mm. Wall thickness of 13 to 14 mm is considered borderline if there are other compelling information (eg, family history of HCM), based on echocardiography. The diagnostic imaging mainly focused on echocardiography, however cardiovascular magnetic resonance (CMR) is used with increasing frequency.[1]
Classification
Causes
Life Threatening Causes
Common Causes
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
| A01 | |||||||||||||||||||||||||||||||||
| B01 | B02 | ||||||||||||||||||||||||||||||||
| C01 | |||||||||||||||||||||||||||||||||
| D01 | D02 | D03 | |||||||||||||||||||||||||||||||
| E01 | E02 | E03 | |||||||||||||||||||||||||||||||
| F01 | F02 | ||||||||||||||||||||||||||||||||
Complete Diagnostic Approach
| A01 | |||||||||||||||||||||||||||||||||
| B01 | B02 | ||||||||||||||||||||||||||||||||
| C01 | |||||||||||||||||||||||||||||||||
| D01 | D02 | D03 | |||||||||||||||||||||||||||||||
| E01 | E02 | E03 | |||||||||||||||||||||||||||||||
| F01 | F02 | ||||||||||||||||||||||||||||||||
Treatment
shown
hidden
Do's
Dont's
References
- ↑ American College of Cardiology Foundation/American Heart Association Task Force on Practice. American Association for Thoracic Surgery. American Society of Echocardiography. American Society of Nuclear Cardiology. Heart Failure Society of America. Heart Rhythm Society; et al. (2011). "2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Thorac Cardiovasc Surg. 142 (6): e153–203. doi:10.1016/j.jtcvs.2011.10.020. PMID 22093723.